Metabolic Blockade in Prostate Cancer: Repurposing SGLT2 Inhibitors as Dual Antitumor and Cardio-Protective Therapy
SGLT2 inhibitors, familiar as diabetes medications like dapagliflozin and canagliflozin, show promise against prostate cancer (and other solid tumors) through targeted metabolic disruption that exploits cancer cells’ addiction to glucose. Prostate tumors frequently overexpress SGLT2 transporters, enabling excessive glucose uptake that fuels the Warburg effect, where cancer cells convert glucose to lactate even in oxygen-rich […]